Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc demonstrates a positive outlook driven by increased confidence in its lead product, KYV-101, particularly in the treatment of myasthenia gravis (MG), with the probability of approval rising to 35% based on promising durability and immediate patient responses. Additionally, KYV-101 shows strong potential in rheumatoid arthritis (RA), outperforming existing therapies like rituximab, indicating its competitive edge in inflammatory and immune diseases. The encouraging early signals observed in multiple autoimmune conditions further support the growth prospects of Kyverna Therapeutics, underscoring its strategic positioning in the biopharmaceutical sector.

Bears say

Kyverna Therapeutics Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the lack of durable responses observed in patients treated with its lead product candidate, KYV-101, for lupus nephritis (LN) and myasthenia gravis (MG). Additionally, there are concerns surrounding the potential failure to generate positive clinical data for KYV-101 in the subset of patients with stimulatory autoimmune disease (SPS), which could hinder further development and commercialization efforts. Furthermore, the company may also encounter long-term dilution risks that could adversely affect shareholder value, compounding the already present uncertainties regarding the efficacy and market potential of its therapies.

KYTX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 3 analysts, KYTX has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.